Ghana s evolving demographic and epidemiological profile will provide increased revenue earning opportunities for pharmaceutical companies, particularly those producing non-communicable disease treatments Local drugmakers are in a favourable position for entering joint ventures with foreign pharmaceutical firms, particularly as regional exports are becoming more important. The Ghanaian government is actively making progress towards fulfilling its ambition of being the Economic Communities of West African States (ECOWAS) hub for pharmaceutical and healthcare investment. The government, in association with foreign aid agencies, is upgrading local capacity. Continental drugmakers familiar with the disease burden and local demand will find licence deals with Ghana s local manufacturers, which require investment in order to diversify portfolio and increase output. Improved healthcare facilities funded by international aid agencies and banks, such as plans for a ----bed teaching hospital funded by the Israeli government. ...Removal of tax on some imported raw pharmaceutical materials will make local manufacturers more competitive. Domestic drugmakers gaining support towards achieving WHO qualification and GMP certification.
...Low affordability levels limit large-scale pharmaceutical spending Financial sustainability will continue limit the success of over Ghana s NHIS. The country s regulatory environment is still in need of supply chain tightening and better policy enforcement. Sporadic price mark-ups on medicines cause regional disparities on the same medicines, hindering access. Cheaper generic imports from abroad need to be carefully controlled to prevent competition from wiping out local drug manufacturing, which also lacks investment finance. The implementation of the Common External Tariff (CET) will threaten Ghana s domestic drug manufacturers, as it favours imports of medicines from cheap manufacturing bases in India and China. ...Cheaper generic imports from abroad need to be carefully controlled to prevent competition from wiping out local drug manufacturing, which also lacks investment finance. The implementation of the Common External Tariff (CET) will threaten Ghana s domestic drug manufacturers, as it favours imports of medicines from cheap manufacturing bases in India and China.
...Ghana has a sizeable population to support large-scale drug manufacturing. Ghana s private healthcare sector attracts medical tourists from Nigeria, boosting sales, especially as medical staff retention and training is generally considered better than in its West African peers. ...